Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress

Contributed by: PR Newswire

Tags

SWEDISH-ORPHAN-Data

More Like This

Sobi announces positive Phase 2 NOBLE results of pegcetacoplan in post-transplant recurrence of primary IC-MPGN and C3G

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN

Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

Sobi Q3 2024 report: Strong growth and significant pipeline momentum

Sobi to present new data at ASH 2023 Annual Meeting

RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort